Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
UNLIMITED Watchlists, Portfolios, Screeners, and other Barchart tools with Barchart Premier. FREE 30 Day Trial
Stocks | Futures | Watchlist | News | More
or
Faster, Cleaner, Better.

Mind Medicine Mindmed Inc (MNMD)

Mind Medicine Mindmed Inc (MNMD)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Quote Overview for [[ item.sessionDateDisplayLong ]]
[[ rowChartData.labelLow ]]
[[ rowChartData.lowPriceFormatted ]]
[[ rowChartData.lowPrice ]]
[[ rowChartData.labelHigh ]]
[[ rowChartData.highPriceFormatted ]]
[[ rowChartData.highPrice ]]
since [[ rowChartData.lowDate ]]
since [[ rowChartData.highDate ]]
[[ value ]] [[ value ]]
Realtime quote and/or trades are not sourced from all markets.

Market News and Commentary

Wall Street Thinks This 1 Psychedelic Stock Can Gain 335% in 2026

Mental health has moved from the margins to the center of the global healthcare conversation. Rising anxiety, depression, and treatment-resistant conditions are stretching traditional therapies to their limits, forcing the industry to search for approaches that go beyond incremental relief. That search has brought psychedelic-assisted therapies back into focus, and this time backed by data, regulation, and serious capital. The space is now gaining legitimacy as clinical results and market demand begin to align.

Within this evolving landscape, Mind Medicine (MNMD) has carved out a clear role. The company, also known as MindMed in short, is developing psychedelic-inspired treatments for...

Fundamentals

See More
  • Market Capitalization, $K 1,322,976
  • Shares Outstanding, K 98,509
  • Annual Sales, $ 0 K
  • Annual Income, $ -108,680 K
  • EBIT $ -151 M
  • EBITDA $ -150 M
  • 60-Month Beta 2.57
  • Price/Sales N/A
  • Price/Cash Flow N/A
  • Price/Book 8.24

Options Overview Details

View History
  • Implied Volatility 94.13% (+0.22%)
  • Historical Volatility 53.59%
  • IV Percentile 71%
  • IV Rank 36.60%
  • IV High 151.81% on 02/05/25
  • IV Low 60.82% on 08/07/25
  • Expected Move (DTE 22) 1.84 (13.73%)
  • Put/Call Vol Ratio 0.79
  • Today's Volume 570
  • Volume Avg (30-Day) 1,117
  • Put/Call OI Ratio 0.21
  • Today's Open Interest 55,238
  • Open Int (30-Day) 60,892
  • Expected Range 11.59 to 15.27

Analyst Rating / Earnings Estimates

Current Rating
See More
Strong Buy
Based on 13 analysts offering recommendations.
Earnings Estimates - Current Qtr 12/31/25
See More
  • Average Estimate -0.48
  • Number of Estimates 4
  • High Estimate -0.37
  • Low Estimate -0.54
  • Prior Year -0.41
  • Growth Rate Est. (year over year) -17.07%

Price Performance

See More
Period Period Low Period High Performance
1-Month
11.64 +15.38%
on 11/25/25
14.28 -5.95%
on 12/23/25
+1.68 (+14.30%)
since 11/24/25
3-Month
9.53 +40.92%
on 09/25/25
14.43 -6.93%
on 10/31/25
+3.61 (+36.76%)
since 09/24/25
52-Week
4.70 +185.74%
on 04/09/25
14.43 -6.93%
on 10/31/25
+6.11 (+83.47%)
since 12/24/24

Most Recent Stories

More News
Wall Street Thinks This 1 Psychedelic Stock Can Gain 335% in 2026

As mental health treatment evolves, MindMed’s advancing psychedelic pipeline and strong 2025 rally have Jones Trading penciling in gains that could more than quadruple the stock from here.

MNMD : 13.43 (-4.21%)
MarketBeat’s Top 5 Rated Small-Cap Stocks

Small-cap stocks are regaining momentum as rate cuts and the end of quantitative tightening drive a renewed risk-on environment.

ATAI : 4.19 (-3.23%)
TRVI : 12.97 (+1.17%)
CRMD : 12.19 (+1.75%)
TREE : 54.12 (+1.86%)
MNMD : 13.43 (-4.21%)
IWM : 252.71 (+0.25%)
MindMed to Present at the 44th Annual J.P. Morgan Healthcare Conference

Mind Medicine (MindMed) Inc. (NASDAQ: MNMD) (the “Company” or “MindMed”), a late-stage clinical biopharmaceutical company developing novel product candidates to treat brain health disorders, today...

MNMD : 13.43 (-4.21%)
MindMed Announces New Employee Inducement Grant

Mind Medicine (MindMed) Inc. (NASDAQ: MNMD) (the “Company” or “MindMed”), a late-stage clinical biopharmaceutical company developing novel product candidates to treat brain health disorders, today...

MNMD : 13.43 (-4.21%)
MindMed Announces New Employee Inducement Grants

Mind Medicine (MindMed) Inc. (NASDAQ: MNMD) (the “Company” or “MindMed”), a late-stage clinical biopharmaceutical company developing novel product candidates to treat brain health disorders, today...

MNMD : 13.43 (-4.21%)
MindMed Reports Q3 2025 Financial Results and Business Updates

-- Anticipated topline data readouts on track for ongoing Phase 3 studies of MM120 Orally Disintegrating Tablet (ODT) in GAD: Voyage (1H 2026) and Panorama (2H 2026)-- ...

MNMD : 13.43 (-4.21%)
MindMed to Participate in Upcoming Investor Conferences

Mind Medicine (MindMed) Inc. (NASDAQ: MNMD) (the “Company” or “MindMed”), a late-stage clinical biopharmaceutical company developing novel product candidates to treat brain health disorders, today...

MNMD : 13.43 (-4.21%)
MindMed Announces New Employee Inducement Grant

Mind Medicine (MindMed) Inc. (NASDAQ: MNMD) (the “Company” or “MindMed”), a late-stage clinical biopharmaceutical company developing novel product candidates to treat brain health disorders, today...

MNMD : 13.43 (-4.21%)
Mind Medicine (MindMed) Inc. Announces Closing of Approximately $259 Million Public Offering, Including Full Exercise of the Underwriters’ Option to Purchase Additional Shares

Mind Medicine (MindMed) Inc . (NASDAQ: MNMD) (the “Company” or “MindMed”), a late-stage clinical biopharmaceutical company developing novel product candidates to treat brain health disorders,...

MNMD : 13.43 (-4.21%)
MindMed to Report Q3 2025 Financial Results on November 6, 2025

Mind Medicine (MindMed) Inc. (NASDAQ: MNMD) (the “Company” or “MindMed”), a late-stage clinical biopharmaceutical company developing novel product candidates to treat brain health disorders, today...

MNMD : 13.43 (-4.21%)

Barchart Technical Opinion

The Barchart Technical Opinion rating is a 100% Buy with a Strengthening short term outlook on maintaining the current direction.

Long term indicators fully support a continuation of the trend.

See More Share

Business Summary

Mind Medicine Inc. is a clinical-stage psychedelic medicine biotech company. It discovers, develops and deploys psychedelic inspired medicines and therapies to address addiction and mental illness. Mind Medicine Inc. is based in New York, United States.

See More

Key Turning Points

3rd Resistance Point 15.00
2nd Resistance Point 14.62
1st Resistance Point 14.02
Last Price 13.43
1st Support Level 13.04
2nd Support Level 12.66
3rd Support Level 12.07

See More

52-Week High 14.43
Last Price 13.43
Fibonacci 61.8% 10.71
Fibonacci 50% 9.57
Fibonacci 38.2% 8.42
52-Week Low 4.70

See More

Want to use this as
your default charts setting?
Save this setup as a Chart Templates
Switch the Market flag
for targeted data from your country of choice.
Open the menu and switch the
Market flag for targeted data from your country of choice.
Want Streaming Chart Updates?
Switch your Site Preferences
to use Interactive Charts
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.
Use your up/down arrows to move through the symbols.
Free Barchart Webinar